ArticleBMC cancer2026
SARS-CoV-2 infection and its effects on toxicity and survival in non-metastatic nasopharyngeal carcinoma: a matched cohort study.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundThis study investigated the impact of SARS-CoV-2 infection on treatment-related adverse events (TRAEs) and 2-year survival outcomes in patients with newly diagnosed non-metastatic nasopharyngeal carcinoma (NPC) treated with radiotherapy alone or in combination with chemotherapy.
methodsIn this retrospective cohort study, 1,108 NPC patients diagnosed between May 2020 and March 2023 were included. Patients were categorized into a SARS-CoV-2-infected group (infection during chemotherapy or during/within 2 weeks after radiotherapy) and an uninfected group. Propensity score matching was performed to minimize selection bias. Primary endpoints were acute and late TRAEs; secondary endpoints included 2-year overall survival (OS), progression-free survival (PFS), distant metastasis-free survival (DMFS), and locoregional recurrence-free survival (LRRFS).
resultsAfter matching, 211 pairs were analyzed. The 2-year OS (96.2% vs. 97.6%; P = 0.403), PFS (88.6% vs. 90.5%; P = 0.558), DMFS (92.4% vs. 91.5%; P = 0.720), and LRRFS (92.4% vs. 96.2%; P = 0.099) were similar between groups. However, SARS-CoV-2-infected patients had higher rates of leukopenia during induction chemotherapy (39.8% vs. 28.9%; P = 0.044) and hepatic impairment during both induction chemotherapy (49.3% vs. 36.0%; P = 0.044) and radiotherapy (26.9% vs. 12.2%; P = 0.001). Cox regression confirmed that SARS-CoV-2 infection was not an independent predictor of survival outcomes.
conclusionsSARS-CoV-2 infection during anticancer therapy in non-metastatic NPC patients was associated with increased hematologic and hepatic toxicities but did not adversely affect 2-year survival outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.